Intralesional Injection of STS in Treatment of Calcinosis
An Open Label Evaluation of Intralesional Injection of Sodium Thiosulfate in the Treatment of Cutaneous or Tendon Calcinosis in Connective Tissue Disease
Robyn T. Domsic, MD, MPH
20 participants
Mar 17, 2025
INTERVENTIONAL
Conditions
Summary
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
Eligibility
Inclusion Criteria5
- Clinical diagnosis of systemic sclerosis, mixed connective tissue disease or inflammatory myopathy
- Must be over 18 years of age
- Participants must be competent to give informed consent
- Participants must have radiographic evidence (xray or ultrasound) of calcinosis.
- Participants must need symptomatic relief
Exclusion Criteria1
- Pregnant women will be excluded
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Depending on the size of the calcinosis lesion, 1-5ml of STS (250mg/ml) will be used for injection under ultrasound guidance.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06672822